Shopko Optical 062 | |
301 Northwest Byp, Great Falls, MT 59404-4125 | |
(406) 727-9724 | |
Not Available |
Full Name | Shopko Optical 062 |
---|---|
Type | Facility |
Speciality | Eyewear Supplier |
Location | 301 Northwest Byp, Great Falls, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902859515 | NPI | - | NPPES |
0550576 | Medicaid | MT | |
213121-20 | Other | EYEMED | |
17877 | Other | MEDICARE | |
35491 | Other | AVESIS |
Mailing Address | Practice Location Address |
---|---|
Shopko Optical 062 301 Northwest Byp, Great Falls, MT 59404-4125 Ph: (406) 727-9724 | Shopko Optical 062 301 Northwest Byp, Great Falls, MT 59404-4125 Ph: (406) 727-9724 |
News Archive
Munich-based digital health company Temedica and healthcare company Roche Pharma AG have announced a joint collaboration in the field of digital support for multiple sclerosis patients.
Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
Better drugs and vaccines are needed to fight HIV/AIDS, tuberculosis (TB), malaria and other tropical diseases. Pharmaceutical research has typically focussed on developing drugs, vaccines and other interventions for diseases prevalent in developed countries, where people can afford to buy treatments; it has tended to overlook those disorders that predominantly affect developing countries.
› Verified 3 days ago